Celulosa Argentina S.A. (BCBA:CELU)

Ligand Pharmaceuticals Balance Sheet

Financials in millions ARS. Fiscal year is June - May.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Nov 30, 2024	May 31, 2024	May 31, 2023	May 31, 2022	May 31, 2021	May 31, 2020
Cash & Equivalents	3,249	14,795	10,940	2,681	969.51	695.8
Short-Term Investments	5,553	4,817	5,971	-	-	-
Cash & Short-Term Investments	8,802	19,612	16,911	2,681	969.51	695.8
Cash Growth	-9.36%	15.97%	530.67%	176.58%	39.34%	35.32%
Accounts Receivable	55,940	37,523	47,357	13,474	6,571	3,960
Other Receivables	7,038	1,553	3,788	651.91	164.27	158.9
Receivables	62,978	39,076	51,144	14,126	6,735	4,119
Inventory	41,511	36,323	28,704	6,805	4,879	3,367
Restricted Cash	-	-	-	292.34	-	-
Other Current Assets	12,284	13,094	8,106	1,844	3,957	381.22
Total Current Assets	125,574	108,105	104,866	25,748	16,541	8,563
Property, Plant & Equipment	244,339	193,904	180,864	50,595	27,688	20,786
Long-Term Investments	33.9	328.1	480.25	8.64	5.11	3.42
Goodwill	798.53	645.68	645.68	171.54	80.07	212.55
Other Intangible Assets	28.21	27.01	54.31	18.11	9.01	6.75
Long-Term Accounts Receivable	-	140.36	248.45	100.93	34.16	39.18
Long-Term Deferred Tax Assets	1,204	723.31	11.45	30.7	4.71	-
Other Long-Term Assets	44,407	38,401	30,257	9,233	4,987	3,640
Total Assets	416,385	342,275	317,427	85,907	49,349	33,251
Accounts Payable	60,176	42,028	47,198	15,201	8,183	4,748
Accrued Expenses	15,180	19,622	19,590	4,713	1,891	1,128
Short-Term Debt	40,643	25,215	21,034	6,098	3,272	1,822
Current Portion of Long-Term Debt	51,525	26,101	41,929	9,667	10,413	7,084
Current Portion of Leases	63.97	56.8	171.72	67.77	12.13	48.59
Current Income Taxes Payable	4,193	5.14	477.87	1,863	223.99	20.36
Current Unearned Revenue	391.94	152.54	5,449	2,670	1,142	276.37
Other Current Liabilities	2,160	4,326	4,343	1,902	1,328	594.07
Total Current Liabilities	174,332	117,506	140,193	42,181	26,463	15,722
Long-Term Debt	74,197	66,787	47,588	17,092	10,192	8,225
Long-Term Leases	99.41	134.7	12.91	44.3	32.12	27.12
Long-Term Deferred Tax Liabilities	55,816	52,183	43,824	15,272	4,361	2,698
Other Long-Term Liabilities	3,837	1,428	7,940	1,095	877.28	281.79
Total Liabilities	308,281	238,039	239,558	75,684	41,926	26,953
Common Stock	100.97	100.94	100.94	100.94	100.94	100.94
Retained Earnings	-144,488	-100,208	-100,485	-35,648	-15,109	-7,965
Comprehensive Income & Other	250,560	202,647	176,578	45,317	22,183	14,003
Total Common Equity	106,173	102,539	76,194	9,770	7,175	6,140
Minority Interest	1,930	1,697	1,675	452.12	248.23	158.3
Shareholders' Equity	108,103	104,236	77,869	10,222	7,423	6,298
Total Liabilities & Equity	416,385	342,275	317,427	85,907	49,349	33,251
Total Debt	166,527	118,295	110,737	32,969	23,921	17,207
Net Cash (Debt)	-157,725	-98,683	-93,825	-30,287	-22,951	-16,511
Net Cash Per Share	-15.63	-9.78	-9.29	-3.00	-2.27	-1.64
Filing Date Shares Outstanding	10,094	10,094	10,094	10,094	10,094	10,094
Total Common Shares Outstanding	10,094	10,094	10,094	10,094	10,094	10,094
Working Capital	-48,758	-9,401	-35,327	-16,432	-9,922	-7,158
Book Value Per Share	10.52	10.16	7.55	0.97	0.71	0.61
Tangible Book Value	105,347	101,867	75,494	9,581	7,086	5,920
Tangible Book Value Per Share	10.44	10.09	7.48	0.95	0.70	0.59
Land	14,488	12,008	15,310	4,310	2,576	2,195
Buildings	21,784	18,006	18,671	5,030	2,688	1,884
Machinery	198,242	160,803	144,811	40,197	21,686	14,293
Construction In Progress	21,470	3,854	2,167	1,740	738.11	562.05

Updated Jan 13, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.